RenovoRx Inc. has provided an update highlighting the commercialization of its FDA-cleared RenovoCath® device, reporting approximately $900,000 in revenue year-to-date through the third quarter of 2025. The company expanded its customer base from five to fourteen approved cancer center customers, with quotes delivered to an additional ten centers. RenovoRx estimates a potential peak annual U.S. revenue opportunity of approximately $400 million for RenovoCath as a stand-alone device and notes the potential to expand its total addressable market over time. The company is also advancing combination therapies utilizing its proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform. Its lead device/drug combination candidate, RenovoCath plus Gemcitabine, has received FDA Orphan Drug Designation for pancreatic and bile duct cancers. The ongoing pivotal Phase III TIGeR-PaC study for locally advanced pancreatic cancer observed increased overall and progression-free survival, with a 65% reduction in side effects at the first interim analysis. The study is expected to complete enrollment in early 2026, with final data anticipated in 2027. RenovoRx reports that its procedures offer shorter hospital visits and outpatient treatment compared to traditional systemic therapies, with a streamlined learning curve for physicians. You can access the full presentation through the link below.